Core Viewpoint - The acquisition of 100% equity in Shenzhen Huada Sanjian Qifa Technology Co., Ltd. and Hangzhou Huada Xufeng Technology Co., Ltd. by the company for approximately 366 million yuan aims to integrate cutting-edge technologies into its operations, establishing a unique competitive advantage in the global life sciences sector [1][3]. Group 1: Acquisition Details - The total transaction price for the acquisition is approximately 366 million yuan [1]. - The acquisition will allow the company to incorporate spatial omics and nanopore sequencing technologies into its product offerings, making it the only global enterprise to cover the entire product matrix of "long-read sequencing + spatial omics" [3]. - The integration will enable the company to provide a one-stop service from library construction, sequencing to data analysis, enhancing customer service capabilities and stickiness [3][5]. Group 2: Strategic Value - The acquisition is strategically significant as it connects short-read (DNBSEQ), long-read (CycloneSEQ), and spatial omics technologies, creating a comprehensive technical chain that is difficult for competitors to replicate [3]. - The spatial omics technology can provide precise navigation for brain-machine interface technologies, laying a core foundation for breakthroughs in this field [3]. Group 3: Pricing and Valuation - The acquisition was made at a stage when the target companies are still in the business incubation phase, allowing for a valuation that reflects the actual asset value and avoids potential overvaluation during commercial maturity [4]. - The assessed value of the target companies is 158 million yuan for Sanjian Qifa and 207.7 million yuan for Xufeng, with a dynamic price-to-sales ratio around 3, significantly lower than industry peers [4]. - Performance commitments from the sellers include a cumulative net profit of no less than 50.1 million yuan for Sanjian Qifa from 2026 to 2028 and 82.8 million yuan for Xufeng from 2028 to 2030, with cash compensation mechanisms in place for unmet targets [4][5]. Group 4: Market Impact - The acquisition is expected to enhance the company's long-term profitability and industry influence, with potential for revenue synergies and commercial realization in cutting-edge sectors [7]. - The deal aligns with industry trends towards deep mergers and acquisitions, positioning the company competitively within the global life sciences and gene sequencing markets [7].

Core Insights - The company BGI Genomics (688114.SH) announced plans to acquire 100% equity of Shenzhen Huada Sanjian Qifa Technology Co., Ltd. and Hangzhou Huada Xufeng Technology Co., Ltd. for a total of 366 million yuan, integrating key assets in spatial omics and nanopore sequencing [1] - This acquisition strengthens BGI Genomics' position in the global gene sequencing market by consolidating its strategic bases in "AI + life sciences + brain-computer interfaces," enhancing its competitive edge in multiple cutting-edge sectors [1][3] Technology Advancements - The long-read sequencing technology (CycloneSEQ) has achieved industry-leading levels in single-chip throughput and methylation direct measurement, comparable to international leader ONT, while the spatial omics technology (Stereo-seq) significantly outperforms similar products from 10X Genomics in capture area, resolution, and multi-level analysis capabilities [2] - Post-acquisition, BGI Genomics will become the only life sciences company globally to cover the entire product matrix of "full-length sequencing + spatial omics," positioning itself as a Chinese version of "Illumina + ONT + 10X Genomics" [2] Strategic Positioning - The acquisition enhances BGI Genomics' first-mover advantage in the cutting-edge sector, particularly in AI healthcare, where its "AI + gene sequencing" strategy is already industry-leading [3] - The integration of Stereo-seq technology provides precise navigation for implantable brain-computer interface technologies, establishing a core foundation for breakthroughs in this field [3] - Market analysts view this acquisition as a cost-effective expansion strategy, allowing the company to secure core assets while building a robust technological moat through unique and leading-edge technology chains [3]